Foregene Co., Ltd. is a leading producer of molecular biology lab reagents and in-vitro diagnostic (IVD) kits, specializing in R&D, production, and marketing. The company is a trailblazer in developing cutting-edge technology platforms in molecular biology, including Direct PCR, double-column RNA isolation and DNA-only silica membrane platforms.
Foregene Co., Ltd. has announced the launch of Cell3 Xtract, a fast, accurate and flexible solution to obtain cell-free DNA (cfDNA) from plasma. Cell3 Xtract’s 90-minute processing time is a game-changer in the field and steps up the plate for other DNA extraction kits in the market.
The kit is designed to extract cfDNA from plasma for various downstream applications, including liquid biopsy, molecular diagnosis, prenatal testing, and clinical monitoring. Liquid biopsy is a novel technique in cancer diagnosis and monitoring, and it requires the extraction of cfDNA from the bloodstream for analysis. Cell3 Xtract's rapid processing time would significantly improve the accuracy and speed of liquid biopsy tests.
“Cell3 Xtract is Foregene Co., Ltd.'s new solution from our molecular biology line-up. It uses a unique silica bead-based system that requires a simple and rapid protocol while maintaining high levels of DNA yield,” said Ryohei Shigemoto, the President of Foregene Co., Ltd.
The conventional DNA extraction process requires DNA to be extracted from fixed tissue for genomic analysis. However, liquid biopsy utilizes the DNA in the bloodstream, eliminating the need for tissue samples. It is less invasive, less risky, and yields more accurate and personalized results.
Foregene Co., Ltd.'s Cell3 Xtract kit employs the silica-bead method, a widely accepted technology for capturing DNA molecules. The labeled beads bind specifically to the cfDNA in plasma, rendering it intact and free from contamination. The company's use of this technology has allowed them to produce a kit with rapid processing time, high yield and flexible extraction. The kit is designed to extract as much DNA as possible, obtaining a high-quality sample suitable for various downstream applications.
The Cell3 Xtract kit comes in three sizes to cater to different plasma volumes. The 50 mL kit can extract up to 100 ng of cfDNA from 2-4 mL of plasma, the 100 mL kit can extract up to 200 ng of cfDNA from 4-8 mL of plasma. The 200 mL kit extracts up to 400 ng of cfDNA from a maximum of 16 mL of plasma. The kit is also compatible with various plasma types, including human, mouse, rat, and monkey.
With Cell3 Xtract, users can extract cfDNA from plasma samples in one easy-to-use kit, cutting down on processing times and effort. The kit employs a simple and user-friendly protocol, making it accessible to researchers of varying skill levels.
“We are optimistic that this kit will positively impact the molecular biology research field and pave the way for personalized medicine. The rapidly changing medical landscape demands better, faster, and more accurate diagnostic tests, and Cell3 Xtract is part of our answer,” said Ryohei Shigemoto.
Foregene Co., Ltd.'s announcement of Cell3 Xtract comes at a fascinating time for the molecular biology research field, as liquid biopsy gains popularity in cancer diagnosis and monitoring. The company's dedication to research and development is reflected in its products, and the launch of Cell3 Xtract underlines the company's commitment to delivering high-quality molecular biology research products.
In conclusion, Foregene Co., Ltd.'s Cell3 Xtract kit will revolutionize the molecular biology field by providing a fast, accurate, and flexible solution for extracting cfDNA from plasma. The company's use of silica bead technology has allowed them to produce a kit with a fast turnaround time, high yield, and flexible extraction capacities. The kit's different sizes and compatibility with various plasma types make it a versatile and accessible kit for researchers at varying skill levels. The launch of Cell3 Xtract cements Foregene Co., Ltd.'s reputation as a leading provider of molecular biology lab reagents and IVD kits.